NEUROCRINE BIOSCIENCES INC Cash and Restricted Cash
NEUROCRINE BIOSCIENCES INC (NBIX) had Cash and Restricted Cash of $338.90 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-31
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $338.90M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $274.50M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $721.00M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $348.20M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $338.90M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $274.50M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $721.00M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $348.20M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $272.00M 10-Q · filed 2026-07-31 | |
| 2025-03-31 | $202.10M 10-Q · filed 2026-05-05 | |
| 2024-12-31 | $241.00M 10-Q · filed 2026-07-31 | |
| 2024-09-30 | $357.10M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $147.70M 10-Q · filed 2025-07-30 | |
| 2024-03-31 | $404.30M 10-Q · filed 2025-05-05 | |
| 2023-12-31 | $259.10M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $301.70M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $168.20M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $111.60M 10-Q · filed 2024-05-01 | |
| 2022-12-31 | $270.70M 10-K · filed 2026-02-11 | |
| 2022-09-30 | $220.00M 10-Q · filed 2023-10-31 | |
| 2022-06-30 | $171.10M 10-Q · filed 2023-08-01 | |
| 2022-03-31 | $278.00M 10-Q · filed 2023-05-03 | |
| 2021-12-31 | $344.00M 10-K · filed 2025-02-10 | |
| 2021-09-30 | $314.30M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $371.20M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $355.80M 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $190.30M 10-K · filed 2024-02-09 | |
| 2020-09-30 | $428.50M 10-Q · filed 2021-11-01 | |
| 2020-06-30 | $418.30M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $190.20M 10-Q · filed 2021-05-05 | |
| 2019-12-31 | $115.50M 10-K · filed 2023-02-09 | $115.48M 10-K · filed 2020-02-07 |
| 2019-09-30 | $171.80M 10-Q · filed 2020-11-09 | $171.81M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $146.50M 10-Q · filed 2020-08-03 | $146.46M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $78.30M 10-Q · filed 2020-05-06 | $78.25M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $147.20M 10-K · filed 2022-02-11 | $147.19M 10-K · filed 2019-02-08 |
| 2018-09-30 | $201.21M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $171.90M 10-Q · filed 2019-07-29 | |
| 2018-03-31 | $179.81M 10-Q · filed 2019-04-29 | |
| 2017-12-31 | $259.20M 10-K · filed 2021-02-05 | $259.21M 10-Q · filed 2018-04-30 |
| 2017-09-30 | $272.43M 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $314.11M 10-Q · filed 2018-07-31 | |
| 2017-03-31 | $69.17M 10-Q · filed 2018-04-30 | |
| 2016-12-31 | $88.15M 10-K · filed 2020-02-07 | |
| 2015-12-31 | $78.99M 10-K · filed 2019-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |